Eli Lilly and Company

Qiagen Genomics, Inc.

Ventirx Pharmaceuticals, Inc.

Operon Biotechnologies, Inc.

Celltech R&d Limited

Array Biopharma Inc.

Ucb S.a.

Rapigene, Inc.

J Jeffry Howbert

John C Tabone

Jeffrey Van Ness

John Thomas Mulligan

Robert F Bruns, Jr

Donald R Gehlert

William H Lunn

Karen Lynn Lobb

Philip Arthur Hipskind

Brian Stephen Muehl

Thomas Alan Crowell

James Arthur Nixon

Joseph H Krushinski, Jr

Bruce D Gitter

Sung Y Cho

John E Toth

James E Ray

Beverley Greenwood

Jon Kevin Reel

Robert Hershberg

David Andrew Neel

Gregory Dietsch

Muralikrishna Duvvuri

Jim P Boyce

Ihab S Darwish

Randy W Jackson

Raymond F Brown

John S Ward

Richard Waltz Harper

Brent Jeffrey Rieder

Hong Woon Yang

David R Helton

James A Aikins

Nathan C Ihle

Eddie V Tao

Kurt Rasmussen

Gerald B Grindey

Fariborz Mohamadi

Venkat Kusukuntla

Cora Sue Grossman

Gerald A Poore

Scott Charles Jeffrey

Pavel Krasik

Ted Baughman

William H W Lunn

Michael M Spees

Kraig M Yager

Alexander Tretyakov

Steven J Mitan

Sung-Yong S Cho

Nathan Nielsen

Ji-Long Jiang

Theodore A Baughman

Dean Maeda

Rob Hershberg

Greg Dietsch

Venkat Reddy Kusukuntla

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

Toll-like receptor agonist formulations and their use

The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.

Methods of synthesis of benzazepine derivatives

Methods and compounds, including compositions therefrom, are provided for determining the sequence of nucleic acid molecules. The methods permit the determination of multiple nucleic acid sequences simultaneously. The compounds are used as tags to generate tagged nucleic acid fragments which are complementary to a selected target nucleic acid molecule. Each tag is correlative with a particular nucleotide and, in a preferred embodiment, is detectable by mass spectrometry. Following separation of the tagged fragments by sequential length, the tags are cleaved from the tagged fragments. In a preferred embodiment, the tags are detected by mass spectrometry and the sequence of the nucleic acid molecule is determined therefrom. The individual steps of the methods can be used in automated format, e.g., by the incorporation into systems.

Methods and compositions for determining the sequence of nucleic acid molecules

This invention is directed to compound of the following formula (I): wherein R, R, Rand Rare as described herein. These compounds and pharmaceutical compositions containing the compounds are useful in treating inflammatory disorders in mammals.

Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents

Tags and linkers specifically designed for a wide variety of nucleic acid reactions are disclosed, which are suitable for a wide variety of nucleic acid reactions wherein separation of nucleic acid molecules based upon size is required.

Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques

Benzobicyclooctane compounds, their use in inhibiting cellular events involving TNF-&#x3b1; and IL-8, and in the treatment of inflammation events in general; a combinatorial library of diverse bicyclooctanes and process for their synthesis as a library and as individual compounds.

Pharmaceutical uses and synthesis of benzobicyclooctanes

This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

Non-peptide tachykinin receptor antagonists

Methods are provided for detecting the binding of a first member to a second member of a ligand pair, comprising the steps of (a) combining a set of first tagged members with a biological sample which may contain one or more second members, under conditions, and for a time sufficient to permit binding of a first member to a second member, wherein said tag is correlative with a particular first member and detectable by non-fluorescent spectrometry, or potentiometry, (b) separating bound first and second members from unbound members, (c) cleaving the tag from the tagged first member, and (d) detecting the tag by non-fluorescent spectrometry, or potentiometry, and therefrom detecting the binding of the first member to the second member.

Methods and compositions for enhancing sensitivity in the analysis of biological-based assays

The synthesis of novel diketopiperazines, their use in inhibiting cellular events such as those involving NFK-&agr;, NFK-&bgr; and in the treatment of inflammation events, a combinatorial library of diverse diketopiperazines and process for their synthesis as a library and as individual compounds. In particular novel diketopiperazines are disclosed including their synthesis and use in cellular events such as activation of the transcription factor, nuclear factor, TNF-&agr;, TNF-&bgr; and also apoptosis.

Pharmaceutical uses and synthesis of diketopiperazines

Piperidinyl and piperazinyl tachykinin receptor antagonists

Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

Growing community of inventors

Bellevue, WA, United States of America

J Jeffry Howbert